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Background: Omega-3 (n-3) fatty acid supplementation is becoming increasingly popular. However given its
antithrombotic properties the potential for severe adverse events (SAE) such as bleeding has safety implications,
particularly in an older adult population. A systematic review of randomized control trials (RCT) was conducted to
explore the potential for SAE and non-severe adverse events (non-SAE) associated with n-3 supplementation in
older adults.
Methods: A comprehensive search strategy using Medline and a variety of other electronic sources was conducted.
Studies investigating the oral administration of n-3 fish oil containing eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA) or both against a placebo were sourced. The primary outcome of interest included reported SAE
associated with n-3 supplementation. Chi-square analyses were conducted on the pooled aggregate of AEs.
Results: Of the 398 citations initially retrieved, a total of 10 studies involving 994 older adults aged ≥60 years were
included in the review. Daily fish oil doses ranged from 0.03 g to 1.86 g EPA and/or DHA with study durations
ranging from 6 to 52 weeks. No SAE were reported and there were no significant differences in the total AE rate
between groups (n-3 intervention group: 53/540; 9.8%; placebo group: 28/454; 6.2%; p = 0.07). Non-SAE relating to
gastrointestinal (GI) disturbances were the most commonly reported however there was no significant increase in
the proportion of GI disturbances reported in participants randomized to the n-3 intervention (n-3 intervention
group: 42/540 (7.8%); placebo group: 24/454 (5.3%); p = 0.18).
Conclusions: The potential for AEs appear mild-moderate at worst and are unlikely to be of clinical significance. The
use of n-3 fatty acids and the potential for SAE should however be further researched to investigate whether this
evidence is consistent at higher doses and in other populations. These results also highlight that well-documented data
outlining the potential for SAE following n-3 supplementation are limited nor adequately reported to draw definitive
conclusions concerning the safety associated with n-3 supplementation. A more rigorous and systematic approach for
monitoring and recording AE data in clinical settings that involve n-3 supplementation is required.
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There is evidence for benefits of long chain omega-3 (n-3)
fatty acids in pathological inflammation [1] including
rheumatoid arthritis [2], crohn’s disease [3], ulcerative col-
itis [4,5], diabetes mellitus [6], cardiovascular events [7-9]
and cancer cachexia [10]. For this reason, various organi-
zations around the world have established dietary recom-
mendations and guidelines for the intake of n-3 fatty acids
(in particular for eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA)) that are focused primarily on
the reduction of cardiovascular disease (CVD) risk [11]. In
Australia and New Zealand, the National Health and
Medical Research Council (NHMRC) suggest a dietary
target for the reduction of chronic disease of 610 and
430 mg/day DHA+ EPA for males and females respect-
ively [12,13]. For the prevention of CVD, the National
Heart Foundation (NHF) of Australia recommends a diet-
ary intake of 500 mg/day EPA +DHA, the equivalent of
two to three servings (150 grams) of oily fish per week
[13]. For adults with diagnosed CVD, a combined dosage
of 1000 mg EPA +DHA per day is recommended which is
best achieved by fish oil supplementation [13].
Fish oil supplementation has become an established
complementary medicine (CM). Data taken from the
2004–05 Australian National Health Survey (NHS) indi-
cated that approximately one-quarter (~1.3 million) of
Australian adults affected by chronic illness regularly used
some form of CM with users more likely to be ≥60 years
and female [14]. Cross-sectional analyses from the Austra-
lian Longitudinal Study of Ageing (ALSA) showed that
cod liver and fish oils were the most frequently used nutri-
tional supplement (excluding vitamin and mineral supple-
mentation) amongst older adults aged ≥65 years [15].
Despite many reviews concentrating on the efficacy of
n-3 fatty acids in various conditions [16-20], the potential
for serious adverse events (SAE) is not well documented,
particularly in older adults. The most commonly raised
concern for administration of n-3 fatty acids is their po-
tential to increase the risk of serious bleeds through their
anti-platelet effects [21-26]. If there is systematic evidence
for serious bleeds or other SAE, the widespread use of n-3
supplementation amongst older adults makes this a public
health concern. At the present time, fish oil use as a sup-
plement or CM remains largely unregulated in Australia
and currently there are no quantity restrictions of key in-
gredients or advisory statements concerning these ingredi-
ents for labelling purposes [27]. Because many n-3 fatty
acid preparations are largely marketed as food supplements,
their potential to contribute to SAE is often overlooked.
The aim of this systematic review was to assess pub-
lished peer reviewed literature of randomized controlled
trials (RCTs) to identify the potential for SAE and non-
serious adverse events (non-SAE) associated with n-3
supplementation in older adults.Archived at Flinders UniversiMethods
Criteria for considering studies for this review
Types of studies
All studies included in this review were RCTs that in-
cluded the oral supplementation of either liquid fish oil
or fish oil capsules, containing EPA, DHA or both, ver-
sus a placebo.
Search methods for identification of studies
Electronic searches We conducted a comprehensive
search strategy using the following electronic data-
bases including MEDLINE (1948 to September 2011),
EMBASE (1980 to March 2011), CINAHL (1982 to
March 2011), SCOPUS (2004 to March 2011) and
THE COCHRANE CENTRAL REGISTAR of CLIN-
ICAL TRIALS (CENTRAL). A search strategy using
free text and MeSH terms was designed for the re-
trieval of studies. Search terms included fish oil, n-3
fatty acids, n-3, EPA, DHA, polyunsaturated fatty
acids (PUFA), long chain fatty acids, geriatrics, eld-
erly, older adults and aged care. The search strategy
was limited to age (≥ 60 years), human studies, re-
stricted to the English language and RCTs. All elec-
tronic databases were searched commencing in
February 2011 ceasing in September 2011.
Eligibility criteria
The criteria for selecting publications for this review
included:
 Elderly persons with a reported mean age
≥ 60 years. Trials that included younger
participants were included if the mean age minus
one standard deviation was greater than 60 years.
Publications that did not report mean age were
excluded.
 Ingestion of liquid fish oil or fish oil capsules
 Study design being a RCT
The exclusion criteria for this review included:
 Review articles and individual patient case studies
 Dietary studies including fish intake or functional
foods containing EPA and/or DHA
 Enteral or Total Parenteral Nutrition (TPN)
administration of EPA and/or DHA
 Participants with known cardiovascular or metabolic
disease, malignancy, renal or liver disease at study
entry
 Participants with known CVD risk factors
(e.g. hypertension, hypertriglyceridemia,
hypercholesterolemia and type 2 diabetes mellitus)
at study entry.
 Non-English languagety: dspace.flinders.edu.au
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Selection of studies An initial screen of titles and ab-
stracts independently by two review authors (AV and
MM) rejected studies that clearly did not meet the inclu-
sion/exclusion criteria. Publications which were unclear
from the title or abstract remained in consideration. A
final round of evaluation was performed by the same
two review authors who independently reviewed each
article (full text) against the defined inclusion/exclusion
criteria. The reviewers resolved any disagreement by
consensus. For publications that passed the final round
of evaluation, the same two review authors identified the
primary outcomes of interest, i.e. SAE and/or non-SAE
following the oral administration of n-3 fatty acid
supplementation.
Intensity classification of adverse events
For the purposes of the present review, reported AEs
from all reviewed studies were classified as either SAE
or non-SAE. The review authors defined SAE as death,
stroke, bleeding or major bruising. Non-SAE were iden-
tified as gastrointestinal (GI) disturbances (vomiting,
halitosis indigestion, pain, flatulence, diarrhoea, nausea
or eructation). Identification and documentation of AEs
in each of the reviewed articles were self-reported by
study participants and/or reviewed by the clinical inves-
tigators in each of the reviewed studies.
Data extraction and management
Using a pre-designed data extraction form, two review
authors (AV and MM) evaluated the selected studies for
review. The data extraction form was piloted against three
publications in the present review and relevant changes
were made to the form. The remaining studies were then
evaluated. The data extraction form included a description
of the types of participants, the dose and duration of EPA
and/or DHA supplementation, the method of measuring
adherence to the EPA and/or DHA intervention as well as
the aim/s and primary findings for each of the reviewed
studies. Any differences in the extraction of data where re-
solved by referring back to the original article followed by
discussion and consensus between all review authors.
Correspondence with authors
An email addressed to the corresponding author from
all reviewed studies was sent requesting any documented
AEs throughout the duration of the study that were not
reported in the full-text article. We used an excel spread
sheet highlighting SAE and non-SAE and requested au-
thors to identify which AEs (if any) were reported in
their study and the number of participants affected. We
also requested that authors identify any additional AEs
that were not highlighted by our correspondence.Archived at Flinders UniversiAssessment of methodological quality of the included studies
The Cochrane Collaboration’s tool for assessing risk of
bias was used by two review authors (AV and MM) to
evaluate all included studies in the present review. This
tool assesses the randomization process (sequence gen-
eration, allocation concealment and blinding), complete-
ness of the data collection (for primary outcomes only)
and the presence of selective reporting. The methodo-
logical quality was further assessed using the Jadad scoring
scale [28]. This instrument was developed to assess RCTs
by ranking them (scale from 0 to 5) against the likelihood
of bias in three item areas which include randomization,
double blinding and withdrawals/dropouts [28].
Statistical analysis
Using a 2 × 2 contingency table, chi-square analysis using
Yates’ correction for continuity were conducted on the
pooled aggregate of SAE and non-SAE to identify signifi-
cant differences in the frequency of reported AEs between
groups. All data were analysed using GraphPad InStat ver-
sion 3.10 for Windows (GraphPad software, San Diego
California, United States of America).
Results
Results of the search
Of the 398 citations initially retrieved through the search
strategy, a total of 113 articles were maintained for a
second round of screening. After reading the full-text ar-
ticles, the second round of screening removed a further
96 articles. The reasons for rejection in the first and sec-
ond screening stages are shown in Figure 1.
A total of 17 full-text articles met the inclusion cri-
teria. However, 11 of the 17 full-text articles were dupli-
cate publications: two studies were reported on two
occasions in separate articles [29-32], one study was
reported on three occasions in separate articles [33-35]
and one study was reported on four occasions in separate
articles [36-39]. In the present review, results reported
from the same trial and population sample and were
treated as a single publication source. Therefore, a total of
10 studies were included in the final review (Table 1).
Trial selection and sample characteristics
The reviewed studies originated from France (n = 2), the
United Kingdom (n = 2), the Netherlands (n = 2), Italy
(n = 1), Sweden (n = 1), Mexico (n = 1), and Iran (n = 1).
All trials were published between 1999 and 2011. The
total number of participants in all reviewed studies was
994 (n-3 treatment group n = 540) with a reported mean
age of 73.5 years.
Study durations and n-3 doses
The duration of the studies reviewed ranged from 6 to
52 weeks. Intervention doses ranged from 0.03 g toty: dspace.flinders.edu.au
Total number of citations retrieved and 
screened; n = 398
Excluded citations: 1st round exclusion
Non RCT study design; n = 79;
Participants with renal impairment, liver disease or malignancy; n = 51;
n = 46;
Participants with CVD or CVD risk factors n = 40;
Dietary studies; e.g. fish intake or functional food containing EPA and/or DHA; n = 27;
Case studies and/or review articles; n = 13;
Duplicates; n = 12;
Enteral or TPN route of administration; n = 11;
Non fish oil administration; n = 3;
Non-English language; n = 2;
Cost effective analysis; n = 1
Total number of citations maintained for 
second round of screening; n = 113
Excluded citations: 2nd round exclusion
Mean age ≤60 years; n = 76;
Dietary studies; e.g. fish intake or functional food containing EPA and/or DHA; n = 14;
Non RCT study design; n = 3;
Non placebo controlled (e.g. no active matched control); n = 2;
Enteral or TPN route of administration; n = 1
RCTs retained and reviewed;                
n = 17(10)
Figure 1 Results of the search strategy for the retrieval of reviewed articles.
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fatty acids were administered via capsules. Rondanelli
et al. 2010 [40] administered n-3 fatty acids as a liquid.
The method of n-3 fatty acid administration was not
specified by Querques et al. 2009 [41].
Reported AEs from included studies
Reported SAE
No SAE attributable to the n-3 intervention were re-
ported. Mortality (2 cases) was reported in one study only
(Van de Rest et al. 2009) [36-39] however the treatment al-
location was not disclosed. These same investigators also
reported a transient ischemic attack (TIA) (1 case) in the
placebo arm [36-39]. Gruenwald et al. 2009 [42] reported
a total of 21 AEs (21/177; (11.8%) throughout the study
duration including 9 that were described as being of
“stronger intensity”. The authors did not differentiate AEs
by treatment allocation, however it was reported that all
AEs were not severe and an association between intake
of the investigational product and reported AEs was
“unlikely”.
Reported non-SAE
All non-SAE are shown in Table 2. GI disturbances were
the most commonly reported AE with five studies
[32,36,40,43,44] reporting GI disturbances (Table 2). Al-
though GI disturbances were generally reported equally
between the n-3 intervention and placebo groups,
Holguin et al. 2005 [44] reported significantly moreArchived at Flinders Universicases of eructation in participants randomized to the n-3
intervention group (n-3 intervention: 11/26 (42.3%);
control group: 4/26 (15.4%); p = 0.04). Freud-Levi et al.
2006 [33-35] reported 9 cases (9/174; 5.2%) of GI distur-
bances and an additional 9 cases of dysphagia secondary
to the size of the study capsules, however the authors
did not differentiate the occurrence of GI disturbances
between treatment allocations. No studies reported
vomiting or halitosis.
Other reported AEs
Four of 10 studies [36,40,42,43] reported ‘other’ AEs that
were not initially considered by the review authors.
These included headache, skin irritation, vertigo, mal-
aise, weight gain, polyurination, restlessness, blurred vi-
sion, sore throat and skeletal muscle pain. The reported
frequencies of these AEs (Table 2) were very low and
unlikely to be attributable to the n-3 intervention alone.
Four authors [31,33,36,45] who responded via email
correspondence reported no additional AEs than those
initially presented in the full-text article.
Anticoagulation exclusions
Four of 10 studies reviewed excluded participants medi-
cated with oral anticoagulants. Fakhrzadeh et al. 2010
[43] excluded participants taking warfarin ≤30 days prior
to study entry. Freund-Levi et al. 2006 [33-35] excluded
participants taking any form of oral anticoagulant medi-
cation, whilst Holguin et al. 2005 [44] only excludedty: dspace.flinders.edu.au
Table 1 Characteristics of included studies
Author, year Mean
age (y)
n-3 dosage (EPA/DHA) Control/placebo Duration Sample
size (n)
Method of
administration
Rondanelli et al. 2010 [40] 84.9 1.67 g/d EPA;
0.83 g/d DHA
Paraffin oil 8 weeks 46 Liquid
a Bechoua et al. 2003 [29] 75.6 30 mg/d EPA
150 mg/d DHA
Sunflower oil 6 weeks 20 Capsules
b Vericel et al. 1999 [30]
Gruenwald et al. 2009 [42] 62.3 0.6 g/d EPA/DHA Glucosamine
sulfate
26 weeks 177 Capsules
a Van de Rest et al. 2009 [36] 69.8 1.8 g/d EPA/DHA
(high-dose);
OR 0.4 g/d EPA/DHA
(low dose)
High-oleic
sunflower oil
26 weeks 302 Capsules
b Bouwens et al. 2009 [39]
c Van de Rest et al. 2008 [37]
d Van de Rest et al. 2008 [38]
Querques et al. 2009 [41] 72.7 0.72 g/d EPA;
0.48 g/d DHA
Usual care 26 weeks 38 Unclear
a Thies et al. 2001 [31] 55-75 0.7 g/d DHA;
OR 0.72 g/d EPA;
0.28 g/d DHA
α-linolenic acid,
γ-linolenic acid,
OR arachidonic acid
12 weeks 46 Capsules
b Thies et al. 2001 [32]
a Vedin et al. 2010 [33] 74 0.6 g/d EPA;
1.72 g/d DHA
Corn oil 52 weeks 174 Capsules
b Vedin et al. 2008 [34]
c Freund-Levi et al. 2006 [35]
Smith et al. 2011 [45] 71 1.86 g/d EPA;
1.5 g/d DHA
Corn oil 8 weeks 15 Capsules
Fakhrzadeh et al. 2010 [43] 74.8 180 mg/d EPA;
120 mg/d DHA
26 weeks 124 Capsules
Holguin et al. 2005 [44] 76.5 2 g/d total marine
triglycerides;
each 1 g containing
83.2% EPA/DHA
Soy oil 26 weeks 52 Capsules
Studies identified by superscripted numbers refer to those derived from the same trial and population sample and are therefore treated as a single publication
source for the purposes of this review.
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other than aspirin. Investigators from Thies et al. 2001
[31,32] excluded participants taking any form of pre-
scribed medication, including aspirin.
Overall AE rate
There was no significant difference (p = 0.07) in the total
AE rate for participants randomized to the n-3 interven-
tion (53/540; 9.8%) compared with those participants
randomized to the placebo arm of studies (28/454;
6.2%). Furthermore, sub-group analyses of pooled non-
SAE related to GI disturbances showed no significant in-
crease in the proportion of reported GI disturbances
among participants randomized to the n-3 interventionArchived at Flinders Universi(n-3 intervention: 42/540 (7.8%); placebo group: 24/454
(5.3%); p = 0.18).
Compliance to the n-3 intervention
Seven of 10 studies reviewed showed an increase in mea-
sures of n-3 fatty acids (EPA and/or DHA) from either
serum, plasma or red blood cell analyses from baseline,
post-intervention [29,31,33,36,40,41,45]. Two studies
(Gruenwald et al. 2009 [42]; Holguin et al. 2005 [44])
assessed compliance by capsule count. Holguin et al.
2005 [44] reported 93.5% compliance whereas the inves-
tigators from Gruenwald et al. 2009 [42] reported only
44% compliance among participants randomized to the
n-3 intervention (Table 1).ty: dspace.flinders.edu.au
Table 2 Minor reported AEs from reviewed studies
Minor AEs Authors Fish oil Placebo
GI disturbances Rondanelli et al. 2010 [40] 6/22 (27.3%) 5/22 (22.7%)
Van de Rest et al. 2009 [36-39] a High dose: 10/96 (10.4%) 12/106 (11.3%)
Low dose: 9/100 (9%)
Thies et al. 2001 [31,32] 1/8 (12.5%) -
Fakhrzadeh et al. 2010 [43] 2/62 (3%) 1/62 (1.5%)
Holguin et al. 2005 [44] 14/26 (53.8%) 6/26 (23.1%)
Headache Rondanelli et al. 2010 [40] - 1/24 (4%)
Skin irritation Gruenwald et al. 2009 [42] 2/90 (2%) -
Van de Rest et al. 2009 [32-35] a - 1/106 (0.9%)
Vertigo Fakhrzadeh et al. 2010 [43] 1/62 (1.5%) -
Malaise Fakhrzadeh et al. 2010 [43] 1/62 (1.5%) -
Van de Rest et al. 2009 [32-35] a Low dose: 1/100 (1%) -
Weight gain Van de Rest et al. 2009 [32-35] a High dose: 1/96 (1%) -
Polyurination Van de Rest et al. 2009 [32-35] a High dose: 1/96 (1%) -
Restlessness Van de Rest et al. 2009 [32-35] a High dose: 1/96 (1%) -
Blurred vision Van de Rest et al. 2009 [32-35] a Low dose: 1/100 (1%) 1/106 (0.9%)
Sore throat Van de Rest et al. 2009 [32-35] a Low dose: 1/100 (1%) -
Skeletal muscle pain Van de Rest et al. 2009 [32-35] a Low dose: 1/100 (1%) 1/106 (0.9%)
a Investigators from Van de Rest et al. 2009 [36-39] included 2 intervention doses of n-3 fish oil; high dose: 1.8 g/d EPA/DHA; low dose: 0.4 g/d EPA/DHA.
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Attention toward adequate sequence generation, alloca-
tion concealment and complete information for outcome
data varied across studies. While the majority of studies
provided a clear outline of the progress of participants
through the trial (i.e. numbers contributing to analyses
at each outcome assessed), the majority of studies lacked
detail on why participants withdrew and the relevant
characteristics of those participants lost to follow-up.
The majority of studies did not clearly identify adequate
sequence generation and therefore the trials were largely
recorded as ‘unknown’. The most common source of
other potential bias was marked differences in baseline
characteristics between the intervention and placebo
groups. The investigators from Van de Rest et al. 2009
[36-39] were the only investigators to adequately address
all components of a high quality methodological study
design. In contrast, the remaining 9 studies were of a
moderate-lower quality in their attention toward the
methodological study design (1 study scoring 5/5, 6 scor-
ing 3/5 and 3 scoring 2/5 according to the Jadad system).
Discussion
We systematically reviewed the potential for AEs in a
population of older adults following an intervention of
n-3 fatty acid supplementation versus a placebo. Our re-
sults are consistent and in support of current literature
showing no evidence of SAE associated with oral n-3Archived at Flinders Universisupplementation in older adults at doses ≤1.86 g EPA
and/or DHA per day. Although non-SAE related to GI
disturbances were observed, these were infrequent and
not solely apparent in the n-3 intervention group.
Current literature in support of an association between
intake of n-3 fatty acids and SAE in an older adult popu-
lation is scant. In the present review, Van de Rest et al.
2009 [36-39] were the only investigators to report on
mortality; however this was deemed unrelated to the
study design or n-3 intervention. These same investiga-
tors also reported one case of a TIA in the placebo arm
of the trial, which was high oleic sunflower oil [36-39].
No studies in the current review reported major bleeds,
stroke or bruising. Of clinical importance, 14 of the 17
full-text articles reported positive benefits associated
with n-3 supplementation in otherwise healthy older
adults; these included reduced symptoms of depression
[40], cell-mediated immunity [29,31,46], a reduction in
oxidative stress [30], relief from osteoarthritic symptoms
[42], anti-inflammatory [33,34,39], anti-atherogenic [39],
increased muscle anabolic signalling [45], cardiovascular
benefits [43,44] and feasibility and acceptability of n-3
fatty acids [41]. With exception to Holguin et al. 2005
[44] who reported a greater prevalence of GI disturbances
(eructation and nausea; ~54%) in participants randomized
to the n-3 intervention group, the AE rate was relatively
low in all other reviewed studies suggesting that the po-
tential benefits associated with moderate-low dose n-3ty: dspace.flinders.edu.au
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no studies in the current review reported negative out-
comes post-intervention.
The potential for undesirable anticoagulant effects
with the concurrent use of fish oil and anticoagulant or
antiplatelet medications have previously been high-
lighted [25,26]. It is speculated that older adults in par-
ticular may have an increased risk of major bleeding due
to increased sensitivity to anticoagulation, multiple
comorbidites and polypharmacy [25]. However, evalu-
ation of the evidence concerning the safety consider-
ations associated with n-3 supplementation shows little
support of an increase risk in bleeding with n-3 intake,
even when concurrently administered with anticoagulant
agents [24]. Despite this Bays 2007 [24] suggested it
would be prudent to discontinue high doses of n-3 fatty
acid supplementation in the days prior to invasive surgi-
cal procedures or in patients at high risk for haemor-
rhagic stroke. Expert opinion by Harris 2007 [47] was
also in agreement suggesting that n-3 fatty acid supple-
mentation does not increase the risk for clinically signifi-
cant bleeding with the proposed cardiovascular benefits
outweighing the theoretical risks for increased bleeding.
In the present review only four of ten studies excluded
participants at study entry medicated with oral anti-
coagulant or antiplatelets despite the theoretical poten-
tial for anticoagulation of n-3 fatty acids. Regardless of
the previous speculation, current evidence has shown
that n-3 supplementation at doses ≤4 g per day, even
when concurrently administered with antiplatelet or
anticoagulant medications, are safe for general consump-
tion [21,48]. However, the doses of n-3 fatty acids in the
present review were considerably smaller compared with
those previously reported suggesting caution may need
to be applied when administering higher doses until fur-
ther evidence is obtained. Although the majority of stud-
ies in the present review (8/10 studies) indicated
compliance toward the n-3 intervention, a dose–re-
sponse relationship between n-3 intake and the potential
for AE is unclear given the uncertainty associated with
the exact quantity of EPA/DHA ingested in the majority
of studies.
Despite the lack of evidence supporting previous rec-
ommendations concerning cessation of n-3 supplemen-
tation, we recognize that the population group in the
present review are non-surgical, older adults free from
CVD or CVD risk factors and are therefore unlikely to
possess the same theoretical complications associated
with bleeding tendency as those with a diagnosis of
CVD or with CVD risk factors. Furthermore, it must
also be noted that while our findings demonstrated no
significant differences in the total AE rate between
groups, this was based only on a small number of stud-
ies (n = 10) of variable quality. Of further importanceArchived at Flinders Universiwas the general lack of consistency in the systematic ap-
proach for the recording of all AEs in each of the indi-
vidual studies. Recognizing this as a potential limitation,
the authors of the present review attempted to address
this by email correspondence to each corresponding au-
thor, however much of the AE data reported in the
present review and documented in each of the studies
are mainly qualitative and therefore may underestimate
nor appropriately describe all potential AEs associated
with n-3 supplementation. For example, there are some
concerns raised over the potential adverse effect on
LDL-cholesterol and the subsequent increased suscepti-
bility to oxidation following n-3 supplementation [49-52].
Additionally, despite certain types of large predatory fish
including shark, swordfish and king mackerel containing
higher sources of methyl mercury, fish oil preparations
supplemented in smaller doses (1-3 g/d) are unlikely to
pose SAE related to methyl mercury and/or other contam-
inants including dioxins and polychlorinated biphenyls
(PCBs) [24,50,53]. Moreover, the level of mercury and
other environmental toxins present in commercially avail-
able fish oil preparations are likely to be negligible given
the extensive purification process to remove these [24,53].
However, the potential harm from methyl mercury and/or
other environmental contaminants subsequent to long-
term exposure at higher doses is less well understood.
Minor intolerances to fish oil are not unusual with
symptoms including eructation, nausea, aversion to
odour and diarrhoea commonly reported [16,24,54,55].
In keeping with this, our review showed that in an older
adult population non-SAE related to GI disturbances
were the most commonly reported. Despite this, we ob-
served no significant differences in the frequency of
reported GI disturbances between groups, suggesting
that the fatty acid composition of fish oil (i.e. EPA and
DHA) is unlikely to be the contributing factor for non-
SAE. Furthermore, the main placebo(s) used in each of
the reviewed studies were typically sunflower or corn oil
(n-6 fatty acids) which have both previously demon-
strated similar non-SAE as described in the present re-
view [56,57]. Results from a recent palatability study in
older adults ≥60 years showed that an association be-
tween reported non-SAE and n-3 fatty acid supplemen-
tation was unlikely [58]. Using various doses of liquid
fish oil (10%, 40% and 100%; containing 5.2 g EPA and
3.6 g DHA at 100% concentrations) Yaxley et al. 2011
[58] reported that older adults were unable to distin-
guish between varying doses of liquid fish oil and most
would not cease consumption if non-SAE such as GI
disturbances were experienced.
Fish oils are naturally highly unstable, making them
susceptible to oxidation and rancidity [24]. For this rea-
son, many individuals are concerned about taking fish
oils as they fear unwanted side effects such as eructationty: dspace.flinders.edu.au
Villani et al. BMC Geriatrics 2013, 13:41 Page 8 of 9
http://www.biomedcentral.com/1471-2318/13/41and diarrhoea. Episodes of GI disturbances may be mini-
mized by avoiding aerated drinks at the time of ingestion
and by consuming fish oil immediately before meals
without further (excessive) fluid consumption [54]. More-
over, tolerance can be improved by refrigerating fish oil
supplements (particularly liquid fish oil) once opened
[24,54]. Results from the present review suggest that it is
feasible that non-SAE relating to taste and smell are asso-
ciated with personal taste and perception, rather than a
physiological rationale. Further improvement in the devel-
opment and manufacturing of fish oil supplements may
improve patient tolerance and perception.Conclusions
The potential for AEs related to n-3 supplementation in
older adults appear mild-moderate at worst, and not of
clinical importance. No reports of SAE including bleed-
ing, stroke or bruising were observed. Non-SAE related
to GI disturbances were the most commonly reported
however these were infrequent and not significantly dif-
ferent when compared against the placebo group. How-
ever this review also highlights that well-documented
data describing the potential for SAE following n-3 sup-
plementation are limited nor adequately reported to
draw definitive conclusions concerning the safety associ-
ated with n-3 supplementation. Although these results
suggest that a low-moderate intake of EPA/DHA appear
safe and acceptable for use in otherwise healthy older
adults, caution should be applied when administering
larger doses until further evidence is positioned. Our re-
view further highlights that a more rigorous and system-
atic approach for monitoring and recording AE data in
clinical settings that involve the use n-3 supplementation
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